POCI

Business Context and Reporting Period

Precision Optics Corporation, Inc. (PEYE) filed its Form 10-Q for the quarterly period ended September 30, 2009. The company designs and manufactures advanced optical instruments, including medical devices like endoscopes and laparoscopes, utilizing proprietary technologies such as Lenslock and micro-precision lenses. The company is classified as a smaller reporting company and a shell company is not applicable. As of November 13, 2009, there were 1,018,411 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased by 5.5% ($36,351) compared to the prior year quarter, primarily due to lower sales of endocouplers and fiber scopes, partially offset by higher sales of an advanced surgical visualization system.
• Gross Margin Compression: Gross profit margin dropped from 46.1% to 35.1%, attributed to lower overall sales volume and a less favorable product mix.
• Expense Reductions:
  • Research and Development (R&D) expenses plummeted 91.7% to $14,647, driven by cost containment plans and increased customer reimbursements for development activities.
  • Selling, General, and Administrative (SG&A) expenses decreased 15.9% to $312,686 due to workforce reductions.
  • Interest expense decreased 65.0% to $64,875 following the full amortization of the debt discount related to the beneficial conversion feature of the 2008 convertible notes.
• Improved Cash Flow: Net cash used in operating activities improved significantly, decreasing from $248,639 in the prior year to $30,041 in the current quarter.

Outlook, Risks, and Management Commentary

• Going Concern Doubt: The company has sustained recurring net losses and negative cash flows. Management states that these factors raise substantial doubt about the company's ability to continue as a going concern. Financial statements are prepared assuming the company will continue as a going concern.
• Liquidity and Debt:
  • Cash on hand is $346,671. Current liabilities exceed current assets by approximately $1,000.
  • Approximately $390,000 of accrued officer salaries and director consulting fees are expected to be settled via restricted common stock rather than cash.
  • Debt Maturity: The 10% Senior Secured Convertible Notes (principal $600,000 plus accrued interest) mature on June 25, 2010. Management states it is highly unlikely they can generate sufficient cash to repay this in full without conversion by holders, refinancing, or renegotiation.
• Product Strategy: The company is focusing on commercializing new products, including Lenslock endoscopes and micro-precision lenses under 1mm, to achieve breakeven. Management expects operating losses to continue through fiscal year 2010 until sales increase.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2009. Material weaknesses were identified regarding segregation of duties (insufficient accounting staff) and inventory valuation controls.

Investor Verification Checklist

• Verify the company's ability to refinance or convert the $600,000 principal plus interest due on the Senior Secured Convertible Notes maturing June 25, 2010.
• Monitor cash burn rate; current cash of $346,671 may be insufficient to fund operations without additional capital or revenue growth.
• Assess the progress of remediation plans for material weaknesses in internal controls, specifically regarding segregation of duties and inventory valuation.
• Track the realization of deferred officer salaries ($390,000) and whether they are settled in stock as anticipated.
• Evaluate the commercial success of new Lenslock and micro-precision lens products, which are critical to the turnaround strategy.